An official website of the United States government
NIH Websites Are Changing Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Trial Status: active
This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose
escalation and expansion study of STK-012 as monotherapy and in combination therapy in
patients with selected advanced solid tumors. The phase 2 portion is a randomized study
of STK-012 in combination with standard of care (SoC) pembrolizumab, pemetrexed, and
carboplatin versus SoC, in patients with first line, PD-L1 negative or STK11 mutated,
non-squamous, non-small cell lung cancer.
Inclusion Criteria
Phase 1: Selected advanced solid tumors
Phase 2:
Diagnosis of non-small cell lung cancer (NSCLC).
Stage IV or Stage IIIB/IIIC and not a candidate for definitive treatment.
Non-squamous (NSQ) cell histology.
No prior systemic therapy for advanced/metastatic NSQ NSCLC.
Must have a tumor that meets at least one of the following criteria on local testing:
PD-L1 negative (TPS <1%), OR;
STK11 mutated on tumor tissue or ctDNA
No known actionable EGFR, ALK, ROS1, or other actionable genomic aberrations for which there is a local standard of care available as front line therapy. Selected
